Marialuisa Barbagallo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marialuisa Barbagallo has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Mantovani
IRCCS Humanitas Research Hospital 14 Rozzano, MI
33 shared publications - Federica Marchesi
University of Milan 1 Milan, Milano
30 shared publications - Fabio Grizzi
Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
25 shared publications - Anna Rita Putignano
IRCCS Humanitas Research Hospital 3 Rozzano, Milano
24 shared publications - Fabio Pasqualini
Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, 20089 Milan, Italy
24 shared publications - Gianluca Basso
IRCCS Humanitas Research Hospital 7 Humanitas Genomic Facility Rozzano, Italy
24 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive Tumor Microenvironment
Patient cohort and relevant clinical information.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive Tumor Microenvironment
Patient cohort and relevant clinical information.
- Open Access
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive Tumor Microenvironment
List of antibodies used in the study and the corresponding experimental conditions.
- 2 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive Tumor Microenvironment
List of antibodies used in the study and the corresponding experimental conditions.
- Open Access
- 30 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (9) , 1370-1385
Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated with an aggressive tumor microenvironment
Macrophages constitute a dominant and functionally diverse immune population within the microenvironment of pancreatic ductal adenocarcinoma (PDAC), yet how macrophage heterogeneity contributes to the tumor remains poorly defined. In an institutional cohort of 145 PDAC specimens, we identified a population of multinucleated giant cells (MGCs) of macrophage origin, an entity previously described in chronic inflammation but rarely in cancer. CD68⁺ MGCs were present in 28% of tumors, enriched in squamous, non-glandular regions, and more frequent after neoadjuvant chemotherapy. By integrating spatial transcriptomics and quantitative imaging, we defined the features of these cells, which, compared with MGCs in non-neoplastic inflammatory lesions, lacked canonical polarization markers (HLA-DR, CD163) and displayed a distinctive transcriptional program characterized by upregulation of the POLR2K, TUBA8, COX5B, and VDAC1 genes, which encode proteins involved in DNA repair, oxidative stress, and MYC signaling. Spatial analyses revealed activation of hypoxia and extracellular matrix–remodeling pathways in MGC-associated niches, and experimental hypoxia promoted MGC formation in vitro. Consistent with these data, we found that in the TCGA PAAD dataset a macrophage MGC gene signature was enriched in the squamous PDAC subtype and correlated with poorer overall survival (p = 0.018). Morphometric and immunofluorescence analyses further showed increased 53BP1⁺Ki67⁺ nuclei and nuclear atypia in MGCs, indicating ongoing proliferation despite DNA damage. Together, these data identify MGCs of macrophage origin as an immune cell state shaped by hypoxia and stress signaling, associated with aggressive tumor phenotypes, and potentially exploitable as an immune classifier in PDAC.
- 30 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (9) , 1370-1385
Open AccessMultinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated with an aggressive tumor microenvironment
Macrophages constitute a dominant and functionally diverse immune population within the microenvironment of pancreatic ductal adenocarcinoma (PDAC), yet how macrophage heterogeneity contributes to the tumor remains poorly defined. In an institutional cohort of 145 PDAC specimens, we identified a population of multinucleated giant cells (MGCs) of macrophage origin, an entity previously described in chronic inflammation but rarely in cancer. CD68⁺ MGCs were present in 28% of tumors, enriched in squamous, non-glandular regions, and more frequent after neoadjuvant chemotherapy. By integrating spatial transcriptomics and quantitative imaging, we defined the features of these cells, which, compared with MGCs in non-neoplastic inflammatory lesions, lacked canonical polarization markers (HLA-DR, CD163) and displayed a distinctive transcriptional program characterized by upregulation of the POLR2K, TUBA8, COX5B, and VDAC1 genes, which encode proteins involved in DNA repair, oxidative stress, and MYC signaling. Spatial analyses revealed activation of hypoxia and extracellular matrix–remodeling pathways in MGC-associated niches, and experimental hypoxia promoted MGC formation in vitro. Consistent with these data, we found that in the TCGA PAAD dataset a macrophage MGC gene signature was enriched in the squamous PDAC subtype and correlated with poorer overall survival (p = 0.018). Morphometric and immunofluorescence analyses further showed increased 53BP1⁺Ki67⁺ nuclei and nuclear atypia in MGCs, indicating ongoing proliferation despite DNA damage. Together, these data identify MGCs of macrophage origin as an immune cell state shaped by hypoxia and stress signaling, associated with aggressive tumor phenotypes, and potentially exploitable as an immune classifier in PDAC.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
Supplementary Table S4 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
Supplementary Table S4 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
Supplementary Table S2 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
Supplementary Table S2 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
Supplementary Figures 1-4, Tables S1 and S5
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
Supplementary Figures 1-4, Tables S1 and S5
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
Supplementary Table S3 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis
Supplementary Table S3 from High-Resolution Analysis of Mononuclear Phagocytes Reveals GPNMB as a Prognostic Marker in Human Colorectal Liver Metastasis